# Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.

> **NCT02583464** · PHASE1 · COMPLETED · sponsor: **Laboratorio Elea Phoenix S.A.** · enrollment: 24 (actual)

## Conditions studied

- Acquired Immunodeficiency Syndrome

## Interventions

- **DRUG:** Tenofovir disoproxil fumarate and emtricitabine

## Key facts

- **NCT ID:** NCT02583464
- **Lead sponsor:** Laboratorio Elea Phoenix S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02583464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02583464, "Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02583464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*